15 UHN Principal Investigators are among the world’s highly cited researchers.
Read More
Image Caption: UHN Principal Investigators were named 2026 Highly Cited Researchers by Clarivate, recognizing research that has been highly cited by peers and has helped shape their respective fields.
Congratulations to the 15 researchers with Principal Investigator (PI) status at UHN who have made Clarivate’s 2026 list of Highly Cited Researchers—identifying the world’s most influential scientists in bibliometrics and analytics. Across 62 countries and regions, 7,090 Highly Cited Researcher designations were awarded to 6,802 individuals.
Citations serve as a widely accepted measure of influence, indicating how frequently a scientific article is referenced in research. The Clarivate Highly Cited Researcher title is a distinct honour for researchers whose publications, over the past decade, rank among the top 1% most-cited publications in their respective fields and publication years.
In addition to this recognition, four of UHN's PIs were awarded the prestigious 'Cross-Field' distinction, representing these researchers' influential work across multiple research fields.
“To be counted among the world’s most cited scientists is to see your ideas taken up, built upon, and put into practice. Our Highly Cited Researchers show us what bold, collaborative science can achieve, and the difference it makes for patients around the world,” says Dr. Brad Wouters, Executive Vice-President of Science and Research at UHN.
The UHN PIs and the categories in which they received their distinction are listed below. To read more, see the Clarivate press release.
Dr. Cheryl Arrowsmith | Cross-Field
Senior Scientist, UHN’s Princess Margaret Cancer Centre
Research focus: Structural and chemical biology of epigenetic regulators related to cancer and drug discovery.
Dr. Gary Bader | Cross-Field
Affiliate Scientist, UHN’s Princess Margaret Cancer Centre and Ajmera Transplant Centre
Research focus: Computational biology approaches that combine molecular and clinical data to understand disease and identify potential therapeutic targets.
Dr. David Cherney | Clinical Medicine
Senior Scientist, UHN’s Organ Systems & Integrated Health Sciences Research Institute
Research focus: The physiological factors that contribute to renal disease in people with diabetes.
Dr. Slava Epelman | Immunology
Senior Scientist, UHN’s Peter Munk Cardiac Centre
Research focus: How immune cells contribute to cardiac tissue injury and repair.
Dr. Eddy Fan | Clinical Medicine
Senior Scientist, UHN’s Lung and Respiratory Diseases Research Institute
Research focus: Advanced life support for acute respiratory failure and patient outcomes following critical illness.
Dr. Anthony Lang | Neuroscience and Behaviour
Senior Scientist, UHN’s Krembil Brain Institute
Research focus: Parkinson disease and other movement disorders, including their causes, progression, diagnosis, and treatment.
Dr. Andres Lozano | Neuroscience and Behaviour
Senior Scientist, UHN’s Krembil Brain Institute
Research focus: Brain mapping, deep brain stimulation and focused ultrasound in patients, and experimental models of brain diseases.
Dr. Tak Mak | Cross-Field
Senior Scientist, UHN’s Princess Margaret Cancer Centre
Research focus: Cellular and molecular mechanisms underlying cancer and immune responses and pathways involved in tumour development.
Dr. Rodrigo Mansur | Psychiatry and Psychology
Clinician Investigator, UHN’s Krembil Brain Institute
Research focus: Combining clinical and neurobiological methods to study mood and metabolic disorders.
Dr. Ozgur Mete | Biology and Biochemistry
Clinician Investigator, UHN’s Princess Margaret Cancer Centre
Research focus: Biomarker discovery for endocrine and neuroendocrine tumours.
Dr. Amit Oza | Clinical Medicine
Senior Scientist, UHN’s Princess Margaret Cancer Centre
Research focus: Targeted therapies and clinical trials for gynecologic cancers.
Dr. Joshua Rosenblat | Psychiatry and Psychology
Clinician Investigator, UHN’s Krembil Brain Institute
Research focus: Treatment-resistant depression, with a focus on pharmacological treatments of mood disorders.
Dr. Matthieu Schapira | Pharmacology and Toxicology
Affiliate Scientist, UHN’s Princess Margaret Cancer Centre
Research focus: Computational approaches to identify new drug targets and study disease-related proteins.
Dr. Lillian Siu | Cross-Field
Senior Scientist, UHN's Princess Margaret Cancer Centre
Research focus: New anticancer drug development, particularly head and neck malignancies.
Dr. Arndt Vogel | Clinical Medicine
Senior Scientist, UHN's Organ Systems & Integrated Health Sciences Research Institute
Research focus: Studying liver cancer evolution, therapy options and strategies, and mechanisms of drug resistance.
Protein analysis identifies heart failure subtypes that could guide future care.
Read More
Image Caption: Determining the molecular changes that underlie the varying causes and symptoms of heart failure could help predict treatment response and identify new drug targets.
Despite medical advances, heart failure (HF) remains a leading cause of death and burden on health care systems around the world. A new study from UHN’s Peter Munk Cardiac Centre and the University of Toronto has identified important molecular differences between patients with HF that may explain differing responses to treatment.
The underlying cause of HF can vary from person to person, and multiple factors may contribute to its development, including inherited heart conditions, previous heart attacks, inflammation of the heart muscle, and damage caused by certain cancer treatments. The multifaceted nature of its development has made understanding the molecular changes associated with HF a challenge.
Despite diverse causes, patients are often treated using similar approaches. As a result, current standards of treatment are not equally as effective for everyone. Understanding differences between patients could help explain why some people respond better to treatment than others and may help pave the way for more personalized treatments.
Proteins influence gene activity and affect signalling pathways that regulate heart function. Due to small sample sizes and difficulty in representing the different types of HF, previous attempts at analyzing the protein profiles of patients with HF have been challenging.
To address these limitations, the research team performed a large-scale analysis of the proteins in heart tissue samples from 149 patients with advanced HF caused by nine different underlying conditions.
The team found that although patients had different clinical symptoms and causes of HF, their heart samples shared many similar molecular changes at end-stage disease. However, further analysis revealed that the samples could be divided into two distinct subgroups based on the expression of proteins linked to fibrosis (scarring) and inflammation during the process of cardiac remodelling—changes to the heart’s size, shape, and function in response to cardiac disease.
The results of an analysis of protein phosphorylation—a type of protein modification that can indicate which signalling proteins are active—supported the subgroup division. This analysis also identified specific signalling molecules associated with a defined subgroup of patients that could be potential drug targets.
In addition, by comparing the pattern of proteins (protein signatures) associated with each subgroup to an independent dataset, researchers found that the subgroups also applied to earlier stages of HF. They found that these protein signatures could be detected in the blood, supporting their potential use as blood-based markers of HF. The protein signatures were also associated with different survival outcomes, providing evidence that they could be used to assess HF prognosis and other characteristics.
Overall, this research provides new insight into the biological differences that underlie HF and may help pave the way for more personalized treatment approaches. Future studies are needed to determine whether the newly identified protein signatures could be targeted to create new treatments and improve patient outcomes.

Dr. Gramolini (left) and Dr. Filio Billia (right); (photo: Ted Rogers Centre for Heart Research)
Dr. Omar Hamed, Postdoctoral Researcher at the University of Toronto, is the first author of this study.
Dr. Anthony Gramolini, Professor in the Department of Physiology at the University of Toronto, is the co-corresponding author of the study.
Dr. Filio Billia, Senior Scientist at UHN’s Peter Munk Cardiac Centre and Ajmera Transplant Centre, and Associate Professor in the Department of Medicine at the University of Toronto, is the co-corresponding author of the study.
This work was supported by the Ted Rogers Centre for Heart Research, the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Canada, and UHN Foundation.
Dr. Anthony Gramolini is the Ted Rogers Chair in Cardiovascular Systems Biology.
Dr. Filio Billia is the Ted Rogers and Family Chair in Heart Function
Hamed O, Reitz CJ, Kuzmanov U, Gramolini S, Hu M, Halpern J, Billia F, Gramolini AO. Cardiac proteomic and phosphoproteomic profiling defines clinically relevant molecular subgroups in human heart failure. Nat Cardiovasc Res. 2026 Oct;5(10):1016-1033. doi: 10.1038/s44161-026-00880-w. Epub 2026 Sep 25.
Global innovation leader Dr. Eyal Zimlichman joins UHN to accelerate health care innovation.
Read More
Image Caption: Dr. Eyal Zimlichman is the inaugural Porter Family Chair in Healthcare Innovation, established to bring world-leading expertise to UHN and accelerate transformative ideas with the potential to improve patient care.
UHN has appointed international health care innovation leader Dr. Eyal Zimlichman as the inaugural Porter Family Chair in Healthcare Innovation.
The Chair is an annual Innovator-in-Residence position for a world-renowned expert who can help advance research and clinical innovation, build new collaborations, and mentor the next generation of innovators. It was created thanks to philanthropic support led by Scotiabank to honour the extraordinary commitment and remarkable leadership that Brian and Megan Porter have demonstrated to UHN and to health care.
Dr. Eyal Zimlichman is an internationally recognized leader in AI, digital health, health care transformation, and venture creation. He is Founder and President of ARC Global and Vice Chairman of Redesign Health. He is also a Professor at Reichman University and Vice-Dean for Innovation at Reichman Medical School. He founded ARC, a validated Digital and AI innovation model, at Sheba in 2019, growing it from a hospital-based innovation program into an international network of health systems.
His experience includes ARC’s approach to digital health and AI innovation, with its design principles, processes, and partnerships, and SPARC, a complementary clinical entrepreneurship education program. At UHN, Dr. Zimlichman will draw on this expertise to provide education, mentorship, and advice on innovation and commercialization, helping foster a culture of leadership.
“As our inaugural Porter Family Chair, Dr. Zimlichman will bring international expertise and new perspectives that will strengthen innovation across UHN to help move promising ideas closer to patient impact,” says Dr. Brad Wouters, Executive Vice President, Science and Research at UHN.
The one-year appointment will also include collaborative innovation projects, UHN-wide seminars, training, and mentorship opportunities.
As part of his first visit to UHN, Dr. Zimlichman will deliver a special seminar, “From Innovation to Transformation and Economic Growth,” on November 17. The presentation will explore how entrepreneurship and commercialization can help transform health care and generate sustainable value. UHN researchers, clinicians, trainees, and staff are invited to attend the seminar and register in advance.
● When: November 17, 2026, 10:00 AM to 11:30 AM ET
● Where: Bob Bell Auditorium, Princess Margaret Cancer Centre, 610 University Avenue, 6th floor, Room 6-604
● How: Register here.
The Porter Family Chair in Healthcare Innovation was made possible through philanthropy and represents a lasting investment in innovation at UHN. UHN extends its sincere thanks to the Porter family and UHN Foundation for helping bring this vision to life and creating new opportunities to improve health care for patients.
A community diversion program could help reduce demand on emergency departments.
Read More
Image Caption: Community-based diversion programs could help reduce pressures on emergency services by providing an alternative care setting for people who do not require emergency medical treatment.
Emergency department (ED) overcrowding can contribute to long wait times and delays in care. It can also affect paramedic services when teams have to wait longer at hospitals to transfer patients, limiting their ability to respond to other emergencies. New research from The Institute for Education Research (TIER) at UHN suggests that community-based programs could help alleviate pressures on emergency services by providing an alternative care setting for people experiencing alcohol or opioid intoxication.
People experiencing substance use problems frequently access EDs, but some cases of intoxication can be safely managed outside of a hospital setting. Diversion programs like sobering centres provide short-term care for individuals recovering from intoxication, offering an alternative for those who do not require emergency medical treatment. Despite their potential to reduce pressures on EDs, little is known about the impact of these programs in Canada.
To address this gap, TIER researchers evaluated service use and impact of the Stabilization and Connection Centre (SCC) in Toronto—a 10-bed ED diversion program that provides short-term stabilization, monitoring, and connections to community supports for people experiencing alcohol or opioid intoxication. The research team analyzed administrative data from the SCC’s first two years of operation, comparing lengths of stay and paramedic transfer-of-care times at the SCC with similar visits at two nearby EDs.
Analyzing 4,574 visits between January 2023 and December 2024, the researchers found that average length of stay at the SCC was over two times longer in comparison to the ED. Paramedics also transferred care significantly faster at the SCC. Longer stays at the SCC may provide more time for support and care outside a busy ED, while shorter transfer times could allow paramedics to return to service sooner and respond to other emergency calls. The SCC also saw more visits on days when the EDs were busier, supporting its potential role as an alternative care destination during periods of higher demand.
Together, the findings highlight how diversion programs may help reduce pressures on EDs and paramedic services while providing an alternative setting for care. Further research is needed to examine patients’ experiences and the program’s effects on long-term outcomes.
Dr. Nick Kerman, first author of the study, is a Research Associate in the lab of Dr. Andrew Boozary.
Dr. Andrew Boozary, senior author of the study, is a Clinician Investigator at The Institute for Education Research at UHN. Dr. Boozary is also the founding Executive Director of UHN’s Gattuso Centre for Social Medicine and an Assistant Professor at the Institute of Health Policy, Management and Evaluation at the University of Toronto.
This work was supported by the Gattuso Centre for Social Medicine at UHN and UHN Foundation.
Kerman N, Hayman K, Vitkin N, Strum RP, Leston F, Luchsinger D, Steer L, Coyle S, O'Connor E, Anderson M, Boozary A. Service use and program-level impacts of a collaborative hospital-community emergency department diversion program for people experiencing alcohol and opioid intoxication. Can J Public Health. 2026 Sep 14. doi: 10.17269/s41997-026-01255-1.
Researchers identify brain changes associated with pain relief after TN treatment.
Read More
Image Caption: Up to 25% of the world is affected by chronic pain conditions such as trigeminal neuralgia (TN)—a form of chronic nerve pain affecting the face and mouth. For those who fail to get relief from standard treatments, understanding why is an essential first step to improving care. (Image: Getty)
A new study from a team at UHN's Krembil Brain Institute (KBI), led by Senior Scientist Dr. Mojgan Hodaie, is shedding light on how specific structural changes in the brain, a form of brain (or neuro) plasticity, are associated with pain relief in trigeminal neuralgia (TN) following surgical treatment. For individuals living with TN—severe chronic neuropathic (nerve) facial pain—these findings may help advance personalized treatment planning and improve understanding of the brain's response to pain relief.
For many patients, trigeminal neuralgia (TN) can be effectively managed with surgery. However, about 25% of individuals do not respond well to surgery. Understanding why remains a challenge in helping more patients achieve effective pain relief.
Prior research from Hodaie's team revealed changes in the anatomy of 13 brain regions among people with TN that could help predict whether a patient was likely to respond to surgery. These regions showed reduced grey matter volume and reduced thickness of the cortex—the outermost layer of the brain. "We wanted to better understand what happens to these regions after treatment, and whether there is a correlation with pain relief," says Dr. Hodaie.
To explore the connection between brain changes and TN symptoms, KBI researchers evaluated MRI scans and pain relief scores from 115 patients with TN before and after surgical treatment.
Comparing imaging before and after surgery, the team observed changes in several brain structures. They identified eight key brain regions where increased thickness of the cortex after surgery was related to improvements in TN symptoms. In general, they found that in these regions, greater thickening between pre- and post-surgery was associated with greater pain relief. One region, the fusiform gyrus—an area of the brain linked to pain-memory—showed the strongest correlation, with post-surgical thickening of the cortex directly linked to pain relief achieved.
These findings give health care providers new insights into the biological processes underlying pain relief in TN. Moreover, they offer evidence that the brain's ability to change and adapt in response to experiences and conditions, a process known as neuroplasticity, may play a key role in the brain's response to chronic pain. For people with TN, this work lays the groundwork for the development of more personalized approaches to treatment in the future. Additional studies will further investigate the role of the fusiform gyrus and explore pain relief from a more multifaceted lens.
Emili Adhamidhis is the first author of this study. She is a medical student at McMaster University's Michael G. DeGroote School of Medicine and a former research trainee who obtained her MSc at UHN's Krembil Brain Institute.
Dr. Mojgan Hodaie, the senior author of this study, is a Senior Scientist at UHN's Krembil Brain Institute, Affiliate Scientist at UHN's KITE Research Institute, and Professor of Surgery (Neurosurgery) at the University of Toronto's Temerty Faculty of Medicine.
This work was supported by the Institute of Medical Science and Temerty Faculty of Medicine at the University of Toronto, and UHN Foundation.
Adhamidhis E, Srisaikaew P, Li J, Latypov TH, Noorani A, Hodaie M. Brain Regional Predictors of Surgical Response Are Dynamically Associated with Post-Surgical Pain Relief in Trigeminal Neuralgia. Brain Sci. 2026 Sep 13;16(9):966.
The 2025–2026 UHN Research Report highlights how discovery is designed to deliver impact.
Read More
Image Caption: The 2025–2026 UHN Research Report features stories of scientists, clinicians, trainees, staff, patients, and partners working together to move discovery into impact.
UHN is pleased to launch the 2025–2026 Research Report: Bold by Design.
Every day across UHN, researchers are asking difficult questions and pursuing solutions to some of health care's most complex challenges. This year's report explores how intentional investments in people, partnerships, technology, and discovery are helping turn those questions into progress for patients and communities.
This report highlights the breadth of work taking place across UHN's research enterprise, including the recruitment of leading scientists through Canada Leads, research examining how environmental factors influence health, and advances in artificial intelligence, wearable technologies, and next-generation medical devices. These stories demonstrate how researchers are bringing together expertise across disciplines to accelerate discovery and move innovation closer to where it can make a difference.
Guided by UHN's Research Strategic Action Plan, UHN's efforts reflect a shared commitment to driving research with impact in mind: advancing knowledge, improving care, and creating new possibilities for the future.
This year's report features research achievements, milestones, and stories from across UHN, including:
● The recruitment of researchers to UHN through Canada Leads in an effort to strengthen Canada's scientific leadership
● Teams investigating the links between environmental factors and human health
● Advances in artificial intelligence and health technologies that support research and care
● New approaches to understanding and treating complex diseases and conditions
● Collaborative efforts that connect science, technology, and clinical expertise to accelerate impact
Join us in celebrating a year of discovery, collaboration, and progress toward A Healthier World.
Read the full 2025–2026 UHN Research Report. Reports from previous years can be found here.
Toronto neuroscience and mental health research community comes together for joint symposium.
Read More
Image Caption: The NEURONTO research symposium was co-hosted by UHN’s Krembil Brain Institute, featuring talks and poster presentations on advancements in neuroscience and mental health research.
On October 8, 2026, UHN’s Krembil Brain Institute (KBI) and The Hospital for Sick Children’s (SickKids) Neurosciences & Mental Health Program (NMH) held the third annual NEURONTO Research Symposium.
With more than 300 registrants, 12 talks, and 100 poster presentations, the event showcased the innovation and collaborative spirit of Toronto’s neuroscience and mental health research community.
Researchers, trainees, and clinicians from KBI, SickKids’ NMH, and the Centre for Addiction and Mental Health came together to exchange ideas, foster new connections, and highlight cutting-edge research taking place across our institutions.
Throughout the day, attendees explored diverse topics, from neuro-immune interactions and dopamine-guided learning to advances in brain imaging and mental health research. Presentations centred on the symposium’s four core themes: glia in health and disease, neural circuits and systems, mental health, and brain imaging and computation.
Thank you to all the speakers, poster presenters, staff, and attendees whose contributions made the symposium such a success. The thoughtful questions and discussions were a reminder of why NEURONTO exists and the impact of collaboration in neuroscience and mental health research.
Research conducted at UHN's research institutes spans the full spectrum of diseases and disciplines, including cancer, cardiovascular sciences, transplantation, neural and sensory sciences, musculoskeletal health, rehabilitation sciences, and community and population health.
Research at UHN is conducted under the umbrella of the following research institutes. Click below to learn more: